Literature DB >> 9108022

RNA splicing specificity determined by the coordinated action of RNA recognition motifs in SR proteins.

S D Chandler1, A Mayeda, J M Yeakley, A R Krainer, X D Fu.   

Abstract

Pre-mRNA splicing requires a large number of RNA-binding proteins that have one or more RNA-recognition motifs (RRMs). Among these is the SR protein family, whose members are essential for splicing and are able to commit pre-mRNAs to the splicing pathway with overlapping but distinct substrate specificity. Some SR proteins, such as SC35, contain an N-terminal RRM and a C-terminal arginine/serine-rich (RS) domain, whereas others, such as SF2/ASF, also contain a second, atypical RRM. Although both the RRMs and the RS domain of SR proteins are required for constitutive splicing, it is unclear which domain(s) defines their substrate specificity, and whether two RRMs in a given SR protein function independently or act coordinately. Using domain swaps between SC35 and SF2/ASF and a functional commitment assay, we demonstrate that individual domains are functional modules, RS domains are interchangeable, and substrate specificity is defined by the RRMs. The atypical RRM of SF2/ASF does not appear to function alone in splicing, but can either activate or suppress the splicing specificity of an N-terminal RRM. Therefore, multiple RRMs in SR proteins act coordinately to achieve a unique spectrum of pre-mRNA substrate specificity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9108022      PMCID: PMC20485          DOI: 10.1073/pnas.94.8.3596

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

Review 1.  Mechanisms for selecting 5' splice sites in mammalian pre-mRNA splicing.

Authors:  D S Horowitz; A R Krainer
Journal:  Trends Genet       Date:  1994-03       Impact factor: 11.639

2.  Modulation of 5' splice site choice in pre-messenger RNA by two distinct steps.

Authors:  W Y Tarn; J A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

3.  Direct interaction of the U1 snRNP-A protein with the upstream efficiency element of the SV40 late polyadenylation signal.

Authors:  C S Lutz; J C Alwine
Journal:  Genes Dev       Date:  1994-03-01       Impact factor: 11.361

4.  Analysis of the RNA-recognition motif and RS and RGG domains: conservation in metazoan pre-mRNA splicing factors.

Authors:  E Birney; S Kumar; A R Krainer
Journal:  Nucleic Acids Res       Date:  1993-12-25       Impact factor: 16.971

5.  Presence of negative and positive cis-acting RNA splicing elements within and flanking the first tat coding exon of human immunodeficiency virus type 1.

Authors:  B A Amendt; D Hesslein; L J Chang; C M Stoltzfus
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

6.  SR proteins promote the first specific recognition of Pre-mRNA and are present together with the U1 small nuclear ribonucleoprotein particle in a general splicing enhancer complex.

Authors:  D Staknis; R Reed
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

7.  The SR protein B52/SRp55 is essential for Drosophila development.

Authors:  H Z Ring; J T Lis
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

8.  Specific interactions between proteins implicated in splice site selection and regulated alternative splicing.

Authors:  J Y Wu; T Maniatis
Journal:  Cell       Date:  1993-12-17       Impact factor: 41.582

9.  Identification of positive and negative splicing regulatory elements within the terminal tat-rev exon of human immunodeficiency virus type 1.

Authors:  A Staffa; A Cochrane
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

10.  The human splicing factors ASF/SF2 and SC35 possess distinct, functionally significant RNA binding specificities.

Authors:  R Tacke; J L Manley
Journal:  EMBO J       Date:  1995-07-17       Impact factor: 11.598

View more
  45 in total

1.  Identification of a bidirectional splicing enhancer: differential involvement of SR proteins in 5' or 3' splice site activation.

Authors:  C F Bourgeois; M Popielarz; G Hildwein; J Stevenin
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

2.  RNA molecules containing exons originating from different members of the cytochrome P450 2C gene subfamily (CYP2C) in human epidermis and liver.

Authors:  P G Zaphiropoulos
Journal:  Nucleic Acids Res       Date:  1999-07-01       Impact factor: 16.971

3.  The splicing factors 9G8 and SRp20 transactivate splicing through different and specific enhancers.

Authors:  Y Cavaloc; C F Bourgeois; L Kister; J Stévenin
Journal:  RNA       Date:  1999-03       Impact factor: 4.942

Review 4.  Sorting out the complexity of SR protein functions.

Authors:  B R Graveley
Journal:  RNA       Date:  2000-09       Impact factor: 4.942

5.  B-cell and plasma-cell splicing differences: a potential role in regulated immunoglobulin RNA processing.

Authors:  Shirley R Bruce; R W Cameron Dingle; Martha L Peterson
Journal:  RNA       Date:  2003-10       Impact factor: 4.942

6.  The second RNA-binding domain of the human splicing factor ASF/SF2 is the critical domain controlling adenovirus E1A alternative 5'-splice site selection.

Authors:  Vita Dauksaite; Göran Akusjärvi
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

7.  Small molecule control of pre-mRNA splicing.

Authors:  Brenton R Graveley
Journal:  RNA       Date:  2005-01-20       Impact factor: 4.942

8.  A role for SRp54 during intron bridging of small introns with pyrimidine tracts upstream of the branch point.

Authors:  C F Kennedy; A Krämer; S M Berget
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

9.  A systematic analysis of the factors that determine the strength of pre-mRNA splicing enhancers.

Authors:  B R Graveley; K J Hertel; T Maniatis
Journal:  EMBO J       Date:  1998-11-16       Impact factor: 11.598

10.  Phosphorylation-dephosphorylation differentially affects activities of splicing factor ASF/SF2.

Authors:  S H Xiao; J L Manley
Journal:  EMBO J       Date:  1998-11-02       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.